Rotavirus Infections - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Rotavirus Infections - Pipeline Review, H2 2018’, provides an overview of the Rotavirus Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rotavirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rotavirus Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rotavirus Infections

- The report reviews pipeline therapeutics for Rotavirus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Rotavirus Infections therapeutics and enlists all their major and minor projects

- The report assesses Rotavirus Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Rotavirus Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Rotavirus Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Rotavirus Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aridis Pharmaceuticals Inc

Beijing Minhai Biotechnology Co Ltd

Bharat Biotech Ltd

Biological E Ltd

Chongqing Zhifei Biological Products Co Ltd

Curevac AG

GlaxoSmithKline Plc

Medicago ...

Aridis Pharmaceuticals Inc

Beijing Minhai Biotechnology Co Ltd

Bharat Biotech Ltd

Biological E Ltd

Chongqing Zhifei Biological Products Co Ltd

Curevac AG

GlaxoSmithKline Plc

Medicago Inc

Serum Institute of India Ltd

UMN Pharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Rotavirus Infections - Overview

Rotavirus Infections - Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Rotavirus Infections - Overview

Rotavirus Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Rotavirus Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rotavirus Infections - Companies Involved in Therapeutics Development

Aridis Pharmaceuticals Inc

Beijing Minhai Biotechnology Co Ltd

Bharat Biotech Ltd

Biological E Ltd

Chongqing Zhifei Biological Products Co Ltd

Curevac AG

GlaxoSmithKline Plc

Medicago Inc

Serum Institute of India Ltd

UMN Pharma Inc

Rotavirus Infections - Drug Profiles

(rotavirus (virus like particle) + typhiod) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-5625 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide for Rotavirus Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rotavac-5C - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus (tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus [Serotype P2-VP8] (monovalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus [Serotype P2] (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus [serotypes G1, G2, G3, G4, P1(8)] (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RV-3BB - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RV-625 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UMN-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rotavirus Infections - Dormant Projects

Rotavirus Infections - Product Development Milestones

Featured News & Press Releases

Jan 24, 2018: India-made rotavirus vaccine achieves World Health Organization prequalification

Sep 21, 2016: Batavia Biosciences receives grant to develop new vaccine against rotavirus

Jun 20, 2013: Medicago Successfully Produces Plant-based Rotavirus VLP Vaccine Candidate

Nov 10, 2012: GSK's Rotarix Vaccine To Help Protect Babies Against Rotavirus

Apr 26, 2012: GSK’s Rotarix To Be Introduced In Ghana

Nov 21, 2011: GSK And Daiichi Sankyo To Launch Rotarix Oral Liquid Formulation To Prevent Rotavirus Gastroenteritis In Japan

May 19, 2010: Health Sciences Authority Provides Update On Review Of Presence Of Porcine Circovirus In GSK's Rotarix

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Rotavirus Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Rotavirus Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Rotavirus Infections - Pipeline by Aridis Pharmaceuticals Inc, H2 2018

Rotavirus Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2018

Rotavirus Infections - Pipeline by Bharat Biotech Ltd, H2 2018

Rotavirus Infections - Pipeline by Biological E Ltd, H2 2018

Rotavirus Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2018

Rotavirus Infections - Pipeline by Curevac AG, H2 2018

Rotavirus Infections - Pipeline by GlaxoSmithKline Plc, H2 2018

Rotavirus Infections - Pipeline by Medicago Inc, H2 2018

Rotavirus Infections - Pipeline by Serum Institute of India Ltd, H2 2018

Rotavirus Infections - Pipeline by UMN Pharma Inc, H2 2018

Rotavirus Infections - Dormant Projects, H2 2018

List of Figures

List of Figures

Number of Products under Development for Rotavirus Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Rotavirus Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports